An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(8 sites)

United States

University of California Los Angeles, Los Angeles, California

Fixel Institute for Neurological Disease, University of Florida Health, Gainesville, Florida

Morsani Center for Advanced Health Care, University of South Florida Health, Tampa, Florida

University of Iowa, Iowa City, Iowa

Uncommon Cures, Chevy Chase, Maryland

Clinilabs Drug Development, Corp., Eatontown, New Jersey

Ohio State University United States, Columbus, Ohio

Children's Hospital of the University of Pennsylvania (CHOP), Philadelphia, Pennsylvania